We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.36B
AUM Growth
+$814M
Cap. Flow
+$435M
Cap. Flow %
9.98%
Top 10 Hldgs %
53.12%
Holding
130
New
25
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$183M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$135M
3
ATNX
Athenex, Inc. Common Stock
ATNX
+$65.5M
4
NVRO
NEVRO CORP.
NVRO
+$44.9M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$37.8M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$89.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$76.6M
3
NVTA
Invitae Corporation
NVTA
+$17.6M
4
IRTC icon
iRhythm Holdings
IRTC
+$15M
5
ZGNX
Zogenix, Inc.
ZGNX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 0.76%
3 Technology 0.14%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
101
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-14,897
Closed -$400K
AGIO icon
102
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-200,000
Closed -$140K
AKBA icon
103
Akebia Therapeutics
AKBA
$338M
– –
-1,703,440
Closed -$14M
ASND icon
104
PUT
Ascendis Pharma A/S
ASND
$16.5B
– –
-200,000
Closed -$25K
EOLS icon
105
Evolus
EOLS
$397M
– –
-15,232
Closed -$344K
KYNB
106
Kyntra Bio
KYNB
$27.4M
– –
-372
Closed -$506K
HUM icon
107
Humana
HUM
$43.9B
– –
-35,000
Closed -$9.31M
IRTC icon
108
iRhythm Holdings
IRTC
$4.02B
– –
-200,000
Closed -$15M
LIVN icon
109
LivaNova
LIVN
$4.47B
– –
-40,000
Closed -$3.89M
PRQR icon
110
ProQR Therapeutics
PRQR
$244M
– –
-722,523
Closed -$10M
RARE icon
111
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-50,000
Closed -$3.47M
SRPT icon
112
CALL
Sarepta Therapeutics
SRPT
$1.64B
– –
-100,000
Closed -$421K
VCEL icon
113
Vericel Corp
VCEL
$2.38B
– –
-28,090
Closed -$492K
VCYT icon
114
Veracyte
VCYT
$4.45B
– –
-31,521
Closed -$789K
IMGN
115
CALL
DELISTED
Immunogen Inc
IMGN
– –
-600,000
Closed -$15K
CLVS
116
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-200,000
Closed -$125K
CLVS
117
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-200,000
Closed -$660K
XENT
118
DELISTED
Intersect ENT, Inc
XENT
– –
-70,000
Closed -$2.25M
IMMU
119
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-200,000
Closed -$125K
AVDR
120
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-100,000
Closed -$1.23M
ONCS
121
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-136
Closed -$17K
BEAT
122
DELISTED
BioTelemetry, Inc.
BEAT
– –
-6,369
Closed -$399K
OMED
123
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-1,719,111
Closed -$1.79M
1 2 3 4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Perceptive Advisors held 130 positions worth $4.36B, up 23% from $3.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $435M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was BridgeBio Pharma: 6,706,268 shares worth $181M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $89.6M trimmed.

  • Perceptive Advisors's largest Q2 2019 buy was BridgeBio Pharma: 6,706,268 shares worth $181M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $135M increase.
  • Perceptive Advisors's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $89.6M.
  • Perceptive Advisors fully exited iRhythm Holdings in Q2 2019, selling an estimated $15M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $4.36B portfolio in Q2 2019.
  • Perceptive Advisors opened 25 new positions and closed 26 in Q2 2019.
  • Perceptive Advisors's portfolio value rose 23% quarter-over-quarter to $4.36B.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.